Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

Income Statement

Follow revenue through to earnings.

Revenue

$72.95M

FY 2025 · Annual

+75.8% YoY

Operating Income

-$33.08M

FY 2025 · Annual

Net Income

-$67.59M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

CLLS Earnings Waterfall · TTM

NASDAQ:CLLS · Revenue to Net Income

Key Ratios

EPS$-0.68
Gross Margin67.9%
Net Margin-175.2%
P/E Ratio27.7
P/S Ratio29.7

Analysis

$68.1M of revenue converted into -$67.3M of net income for the selected period. Gross margin is 67.9% and net margin is -175.2%, showing how much revenue survives after costs and taxes. EPS is $-0.68, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 13, 2026
6-K6-K filingNov 12, 2026
SC 13D/ASC 13D/A filingNov 9, 2026
6-K6-K filingNov 9, 2026
6-K6-K filingOct 28, 2026

How much revenue does CLLS generate?

Cellectis S.A. (CLLS) reported $72.95M of revenue in fiscal 2025.

Is CLLS profitable?

Cellectis S.A. (CLLS) reported -$67.59M of net income, with a net margin of -92.7%.